Myelodysplastic Syndrome Clinical Trial

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary

The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).

View Full Description

Full Description

This is an open-label study to evaluate pegcetacoplan in people with PNH who are 12-17 years old. The study will consist of a 4-week screening period followed by a 16-week treatment period. Participants switching from a C5 inhibitor will have an additional 4 week run-in period between the screening and treatment periods. At the completion of the study treatment period, participants will either enter a long-term extension period or a 2-month follow-up period.

All eligible study participants will receive pegcetacoplan, administered via subcutaneous infusion twice a week at home. The subcutaneous infusion requires two small needles to be inserted into the fatty layer of tissue under the skin and the investigational medication will flow into the body. Study participants and/or caregivers will be trained on home administration of pegcetacoplan.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Are 12-17 years old at the time of screening
Weigh at least 20 kg (approx. 44 lbs)
Have the diagnosis of PNH, confirmed by high-sensitivity flow cytometry (granulocyte or monocyte clone >10%)

EITHER:

Not being treated with an approved complement inhibitor (eculizumab or ravulizumab) prior to start of pegcetacoplan dosing, AND have hemolytic anemia. Hemolytic anemia is defined as hemoglobin (Hb) less than the lower limit of normal (Hb < LLN) and LDH >1.5 times the upper limit of normal (ULN); OR
Currently receiving treatment with an approved complement inhibitor (eculizumab or ravulizumab) AND have evidence of ongoing anemia. Ongoing anemia is defined as Hb < LLN and ARC > ULN
Have a platelet count >75,000/mm3 and an absolute neutrophil count >1000/mm3

Exclusion Criteria:

Are an adult, 18 years of age or older, with PNH
Known or suspected hereditary fructose intolerance (HFI)
History of hereditary complement deficiency, bone marrow transplant, or meningococcal disease (meningitis, bacteremia or septicemia)
Females who are pregnant or breastfeeding

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

12

Study ID:

NCT04901936

Recruitment Status:

Recruiting

Sponsor:

Apellis Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Children's Hospital of Atlanta
Atlanta Georgia, 30329, United States
Motol University Hospital
Prague , 150 0, Czechia
Robert-Debré Hospital Paris
Paris , 75009, France
Hospital Ampang
Ampang , 68000, Malaysia
Radboud University Hospital Nijmegen
Nijmegen , 6525 , Netherlands
University Children's Hospital
Belgrade , 11000, Serbia
University Hospital Vall d'Hebron
Barcelona , E-080, Spain
University Hospital 12 de Octubre
Madrid , E-280, Spain
Phramongkutklao Hospital and College of Medicine
Bangkok , 10400, Thailand
St. Mary's Hospital
London , W2 1N, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 2

Estimated Enrollment:

12

Study ID:

NCT04901936

Recruitment Status:

Recruiting

Sponsor:


Apellis Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.